Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

Bedimo R.

HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10.

2.

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Dhillon S.

Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. Review.

PMID:
21668043
3.

Spotlight on tesamorelin in HIV-associated lipodystrophy.

Dhillon S.

BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000. Review.

PMID:
22050344
4.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.

PMID:
20554713
5.

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Sivakumar T, Mechanic O, Fehmie DA, Paul B.

HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. Review.

6.

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

N Engl J Med. 2007 Dec 6;357(23):2359-70.

7.

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Spooner LM, Olin JL.

Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. Review.

PMID:
22298602
8.

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.

JAMA. 2014 Jul 23-30;312(4):380-9. doi: 10.1001/jama.2014.8334.

9.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
10.

Pathogenesis and treatment of HIV lipohypertrophy.

Leung VL, Glesby MJ.

Curr Opin Infect Dis. 2011 Feb;24(1):43-9. doi: 10.1097/QCO.0b013e3283420eef. Review.

11.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.

PMID:
20101189
12.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058.

PMID:
18690162
13.

Treatment options for HIV-associated central fat accumulation.

Cofrancesco J Jr, Freedland E, McComsey G.

AIDS Patient Care STDS. 2009 Jan;23(1):5-18. doi: 10.1089/apc.2008.0067. Review.

PMID:
19055407
14.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.

15.

Approach to the human immunodeficiency virus-infected patient with lipodystrophy.

Brown TT.

J Clin Endocrinol Metab. 2008 Aug;93(8):2937-45. doi: 10.1210/jc.2008-1019. Review.

16.
17.

Lipodystrophy in HIV patients: its challenges and management approaches.

Singhania R, Kotler DP.

HIV AIDS (Auckl). 2011;3:135-43. doi: 10.2147/HIV.S14562. Epub 2011 Dec 14.

18.

Tesamorelin, a human growth hormone releasing factor analogue.

Wang Y, Tomlinson B.

Expert Opin Investig Drugs. 2009 Mar;18(3):303-10. doi: 10.1517/13543780802707658 . Review.

PMID:
19243281
19.
20.

Growth hormone deficiency and human immunodeficiency virus.

Rochira V, Guaraldi G.

Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):91-111. doi: 10.1016/j.beem.2017.02.006. Epub 2017 Feb 24. Review.

PMID:
28477736

Supplemental Content

Support Center